Insight

Dec 16, 2024, 17:31

GemCis-NabPaclitaxel vs. GemCis in first line of advanced biliary tract cancers

Erman Akkus shared on X:

“GemCis-NabPaclitaxel vs. GemCis in 1L of advanced biliary tract cancers

SWOG S1815

No PFS or OS benefit

PFS benefit in gallbladder cancer subgroup.”

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Authors: Rachna T. Shroff, Gentry King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Imane El Dika, Benjamin Tan, Puneet Cheema, Anuj Patel, Renuka Iyer, R. Katie Kelley, Jaykumar Thumar, Anthony El-Khoueiry, Katherine A. Guthrie, E. Gabriela Chiorean, Howard Hochster, and Philip A. Philip.

GemCis-NabPaclitaxel vs. GemCis in first line of advanced biliary tract cancers

Aaron J. Scott Amit Mahipal Anthony El-Khoueiry Anuj Patel Aparna Kalyan Benjamin Tan cancer E. Gabriela Chiorean Erman Akkus Gentry King Howard Hochster Imane El Dika Jaykumar Thumar Katherine A. Guthrie Khalid Matin Laura Goff Milind M. Javle Mitesh J. Borad OncoDaily Oncology Philip A. Philip Puneet Cheema R. Katie Kelley Rachna T. Shroff Renuka Iyer Sarah Colby

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage